Patrick Chi-Chung Ma, MD, MSc - Penn State Cancer Institute
Researcher Profile
Patrick Chi-Chung Ma, MD, MSc
Professor, Department of Medicine
Interim Chief, Division of Hematology and Oncology
Interim Chief, Division of Hematology and Oncology
Scientific Program:Next-Generation Therapies
Research Interests
- Therapeutics
- Neoplasms
- Non-Small Cell Lung Carcinoma
- Lung Neoplasms
- Mutation
- Small Cell Lung Carcinoma
- ErbB Receptors
- Hepatocyte Growth Factor
- Neoplasm Metastasis
- Protein-Tyrosine Kinases
- Adenocarcinoma of Lung
- Erlotinib Hydrochloride
Clinical Trials
A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy With or Without SBRT for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer
KEYSTROKE: A Randomized Phase II Study of Pembrolizumab (KEYTRUDA®) Plus Stereotactic Re-irradiation Versus SBRT Alone for Locoregionally Recurrent or Second Primary Head and Neck Carcinoma
A Phase II, Multicenter, Randomized, Open-Label Trial of GEN1046 as monotherapy and in Combination with Anti-cancer Therapy in Subjects with Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer who failed first-line Standard of Care therapy with an Immune Checkpoint Inhibitor
APG-115 - A Phase Ib/II Study of APG-115 in Combination with Pembrolizumab in Patients with Unresectable or Metastatic Melanomas or Advanced Solid Tumors
A Phase I/II Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C mutation (MRT849-001)
Phase 1/2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
A Phase II/III Randomized Study of Maintenance Nivolumab versus Observation in Patients with Locally Advanced, Intermediate Risk HPV Positive OPCA
NRG HN009- Randomized Phase II/III Trial of Radiation with High-Dose Cisplatin (100 mg/m2) Every Three Weeks Versus Radiation with Low-Dose Weekly Cisplatin (40 mg/m2) for Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
S1914 A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT versus SBRT Alone in High Risk, Early Stage NSCLC
A randomized phase II trial of adjuvant Pembrolizumab versus observation following curative resection for stage I non-small cell lung cancer (NSCLC) with primary tumors between 1-4 cm: Big Ten Cancer Research Consortium BTCRC-LUN18-153
NRG-LU007 Randomized Phase II/III Trial Of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR trial
Recent Publications
2023
Guo, T, Zhao, S, Wang, P, Xue, X, Zhang, Y, Yang, M, Li, N, Li, Z, Xu, L, Jiang, L, Zhao, L, Ma, PC, Rosell, R, Li, J & Gu, C 2023, 'Erratum: YB-1 regulates tumor growth by promoting MACC1/c-Met pathway in human lung adenocarcinoma (Oncotarget (2017) 8 (48110-48125) DOI: 10.18632/oncotarget.18262)', Oncotarget, vol. 14, no. 1, pp. 280. https://doi.org/10.18632/oncotarget.28393
2022
Kim, SY, Yin, J, Bohlman, S, Walker, P, Dacic, S, Kim, C, Khan, H, Liu, SV, Ma, PC, Nagasaka, M, Reckamp, KL, Abraham, J, Uprety, D, Wang, F, Xiu, J, Zhang, J, Cheng, H & Halmos, B 2022, 'Characterization of MET Exon 14 Skipping Alterations (in NSCLC) and Identification of Potential Therapeutic Targets Using Whole Transcriptome Sequencing', JTO Clinical and Research Reports, vol. 3, no. 9, 100381. https://doi.org/10.1016/j.jtocrr.2022.100381
Esposito, R, Polidori, T, Meise, DF, Pulido-Quetglas, C, Chouvardas, P, Forster, S, Schaerer, P, Kobel, A, Schlatter, J, Kerkhof, E, Roemmele, M, Rice, ES, Zhu, L, Lanzós, A, Guillen-Ramirez, HA, Basile, G, Carrozzo, I, Vancura, A, Ullrich, S, Andrades, A, Harvey, D, Medina, PP, Ma, PC, Haefliger, S, Wang, X, Martinez, I, Ochsenbein, AF, Riether, C & Johnson, R 2022, 'Multi-hallmark long noncoding RNA maps reveal non-small cell lung cancer vulnerabilities', Cell Genomics, vol. 2, no. 9, 100171. https://doi.org/10.1016/j.xgen.2022.100171
Shen, C, Holguin, RAP, Schaefer, E, Zhou, S, Belani, CP, Ma, PC & Reed, MF 2022, 'Utilization and costs of epidermal growth factor receptor mutation testing and targeted therapy in Medicare patients with metastatic lung adenocarcinoma', BMC health services research, vol. 22, no. 1, 470. https://doi.org/10.1186/s12913-022-07857-y
2021
Mattes, MD, Eubank, TD, Almubarak, M, Wen, S, Marano, GD, Jacobson, GM & Ma, PC 2021, 'A Prospective Trial Evaluating the Safety and Systemic Response From the Concurrent Use of Radiation Therapy with Checkpoint Inhibitor Immunotherapy in Metastatic Non–Small Cell Lung Cancer', Clinical Lung Cancer, vol. 22, no. 4, pp. 268-273. https://doi.org/10.1016/j.cllc.2021.01.012
Ma, PC 2021, 'ADAURA: The role of adjuvant EGFR TKI and future consideration (Pro)', Precision Cancer Medicine, vol. 4, no. March, 6. https://doi.org/10.21037/pcm-2020-mnsclc-10
Khan, SA, Sun, Z, Dahlberg, S, Malhotra, J, Keresztes, R, Ikpeazu, C, Ma, P, Ramalingam, SS & Pillai, R 2021, 'Efficacy and Safety of Glembatumumab Vedotin in Patients With Advanced or Metastatic Squamous Cell Carcinoma of the Lung (PrECOG 0504)', JTO Clinical and Research Reports, vol. 2, no. 5, 100166. https://doi.org/10.1016/j.jtocrr.2021.100166
He, Y, Chen, L, Zhao, L, Dang, S, Liu, G, Sasada, S, Ma, PC, Zandwijk, NV, Rosell, R, Popper, HH, Wang, H, Jiang, M, Guo, H, Liu, X, Chen, S, Zhang, X, Xu, M, Zhu, B, Liu, M & Zhou, C 2021, 'Genomic and transcriptional alterations in first-line chemotherapy exert a potentially unfavorable influence on subsequent immunotherapy in NSCLC', Theranostics, vol. 11, no. 14, pp. 7092-7109. https://doi.org/10.7150/thno.58039
Albandar, HJ, Fuqua, J, Albandar, JM, Safi, S, Merrill, SA & Ma, PC 2021, 'Immune-related adverse events (Irae) in cancer immune checkpoint inhibitors (ici) and survival outcomes correlation: To rechallenge or not?', Cancers, vol. 13, no. 5, 989, pp. 1-15. https://doi.org/10.3390/cancers13050989
Nagasaka, M, Asad, MFB, Al Hallak, MN, Uddin, MH, Sukari, A, Baca, Y, Xiu, J, Magee, D, Mamdani, H, Uprety, D, Kim, C, Xia, B, Liu, SV, Nieva, JJ, Lopes, G, Bepler, G, Borghaei, H, Demeure, MJ, Raez, LE, Ma, PC, Puri, S, Korn, WM & Azmi, AS 2021, 'Impact of XPO1 mutations on survival outcomes in metastatic non-small cell lung cancer (NSCLC)', Lung Cancer, vol. 160, pp. 92-98. https://doi.org/10.1016/j.lungcan.2021.08.010
Lee, M, Jain, P, Wang, F, Ma, PC, Borczuk, A & Halmos, B 2021, 'MET alterations and their impact on the future of non-small cell lung cancer (NSCLC) targeted therapies', Expert Opinion on Therapeutic Targets, vol. 25, no. 4, pp. 249-268. https://doi.org/10.1080/14728222.2021.1925648
2020
Attia, CG, Fei, N, Almubarak, M, Ma, PC & Mattes, MD 2020, 'Patterns of disease progression to checkpoint inhibitor immunotherapy in patients with stage IV non-small cell lung cancer', Journal of Medical Imaging and Radiation Oncology, vol. 64, no. 6, pp. 866-872. https://doi.org/10.1111/1754-9485.13096
Brownmiller, T, Juric, JA, Ivey, AD, Harvey, BM, Westemeier, ES, Winters, MT, Stevens, AM, Stanley, AN, Hayes, KE, Sprowls, SA, Gatesman Ammer, AS, Walker, M, Bey, EA, Wu, X, Lim, ZF, Zhu, L, Wen, S, Hu, G, Ma, PC & Martinez, I 2020, 'Y chromosome LncRNA are involved in radiation response of male non-small cell lung cancer cells', Cancer Research, vol. 80, no. 19, pp. 4046-4057. https://doi.org/10.1158/0008-5472.CAN-19-4032